Morgan Stanley has downgraded 10X Genomics Inc (TXG) to Equal-Weight from Overweight as of December 1, 2025. The current share price stands at $17.95.
This move underscores a shift in sentiment regarding the company's outlook, potentially indicating increased caution amid competitive pressures and execution risks that could affect performance.
10X Genomics, headquartered in Pleasanton, California, operates within the Life Sciences Tools & Services industry. The company focuses on developing products that enhance the understanding of biology through integrated solutions, including instruments and software for single-cell and spatial biology systems. With a market capitalisation of $2.1 billion and a trailing twelve months EPS of -0.62, 10X Genomics is positioned for future growth, albeit with challenges.
The upcoming earnings reports are scheduled for May 6, 2026, and August 5, 2026, with estimated EPS of -0.29 and -0.24 respectively, alongside revenue estimates of $144.0 million and $151.1 million.
Analyst consensus currently shows 5 Strong Buy, 5 Buy, 13 Hold, with no Sell or Strong Sell ratings, reflecting a general optimism despite the recent downgrade. Analyst ratings can evolve as new information becomes available, and they should be viewed as one of many factors when making investment decisions.